SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase

Sorafenib, a first-line drug for advanced hepatocellular carcinoma (HCC), shows a favorable anti-tumor effect while resistance is a barrier impeding patients from benefiting from it. Thus, more efforts are needed to lift this restriction. Herein, we first find that solute carrier family 27 member 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Feng-li, Wu, Xiao-hong, Chen, Chang, Wang, Kai, Huang, Lu-yi, Xia, Jie, Liu, Yi, Shan, Xue-feng, Tang, Ni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837139/
https://www.ncbi.nlm.nih.gov/pubmed/36635256
http://dx.doi.org/10.1038/s41419-023-05558-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837139/
https://www.ncbi.nlm.nih.gov/pubmed/36635256
http://dx.doi.org/10.1038/s41419-023-05558-w

Ejemplares similares